Phase I study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 and intraperitoneal infusion of nafamostat mesilate for gastric cancer with peritoneal dissemination

Phase I study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 and intraperitoneal infusion of nafamostat mesilate for gastric cancer with peritoneal dissemination - Phase I study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 and intraperitoneal infusion of nafamostat mesilate for gastric cancer with peritoneal dissemination

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018658

Enrollment

Registered

2015-09-01

Start date

2013-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer with peritoneal dissemination

Interventions

Paclitaxel is administered intravenously at 50 mg/m2 and intraperitoneally at 20 mg/m2 on days 1 and 8. Nafamostat mesilate is administered intraperitoneally with an initial dose of 40 mg/body, steppe

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Histologically proven unresectable or recurrent gastric adenocarcinoma; peritoneal dissemination and/or cancer cells on peritoneal cytology; age more than 20 years; Eastern Cooperative Oncology Group performance status 0-1; adequate bone marrow function (leukocyte count 3,000-12,000/mm3, hemoglobin >= 8.0 g/dl, platelets >= 100,000/mm3 ); adequate liver function (AST/ALT </= 100, total bilirubin </=2.0 mg/dL); adequate renal function(BUN </= 1.0 x ULN, serum creatinine </= 1.2mg/dL, creatinine clearance>= 60 ml/min), adequate oral intake, and an expected survival period of more than 3 months.

Exclusion criteria

Exclusion criteria: Metastasis to distant organ sites (such as the liver, lungs or bone), other active concomitant malignancies, or other severe medical conditions (such as pulmonary fibrosis, active infection, uncontrollable heart disease, uncontrollable diabetes mellitus, history of severe drug allergy).

Design outcomes

Primary

Measure	Time frame
To evaluate the safety and determine RD	—

Countries

Japan

Contacts

Public ContactNorio Mitsumori

The Jikei University School of Medicine Division of Gastrointestinal surgery, Department of Surgery

mitsumori@jikei.ac.jp03-3433-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026